Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2.
| العنوان: | Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2. |
|---|---|
| المؤلفون: | Routledge I; Department of Medicine, University of California San Francisco, San Francisco, California, USA., Takahashi S; Department of Medicine, University of California San Francisco, San Francisco, California, USA., Epstein A; Department of Medicine, University of California San Francisco, San Francisco, California, USA., Hakim J; Department of Medicine, University of California San Francisco, San Francisco, California, USA., Janson O; Department of Medicine, University of California San Francisco, San Francisco, California, USA., Turcios K; Department of Medicine, University of California San Francisco, San Francisco, California, USA., Vinden J; Department of Medicine, University of California San Francisco, San Francisco, California, USA.; Infectious Disease and Immunity Graduate Group, University of California Berkeley, Berkeley, California, USA., Risos JT; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Baniqued MR; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Pham L; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Di Germanio C; Vitalant Research Institute, San Francisco, California, USA., Busch M; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.; Vitalant Research Institute, San Francisco, California, USA., Kushel M; Center for Vulnerable Populations, Zuckerberg San Francisco General Hospital and Trauma Center, University of California San Francisco, San Francisco, California, USA., Greenhouse B; Department of Medicine, University of California San Francisco, San Francisco, California, USA., Rodríguez-Barraquer I; Department of Medicine, University of California San Francisco, San Francisco, California, USA. |
| المصدر: | MedRxiv : the preprint server for health sciences [medRxiv] 2021 Oct 20. Date of Electronic Publication: 2021 Oct 20. |
| نوع المنشور: | Preprint |
| اللغة: | English |
| بيانات الدورية: | Country of Publication: United States NLM ID: 101767986 Publication Model: Electronic Cited Medium: Internet NLM ISO Abbreviation: medRxiv Subsets: PubMed not MEDLINE |
| مستخلص: | Background: As COVID-19 vaccines continue to be rolled-out, the "double burden" of health disparities in both exposure to infection and vaccination coverage intersect to determine the current and future patterns of infection, immunity, and mortality. Serology provides a unique opportunity to measure biomarkers of infection and vaccination simultaneously, and to relate these metrics to demographic and geographic factors. Methods: Leveraging algorithmically selected residual serum samples from two hospital networks in San Francisco, we sampled 1014 individuals during February 2021, capturing transmission during the first 11 months of the epidemic and the early roll out of vaccination. These samples were tested using two serologic assays: one detecting antibodies elicited by infection, and not by vaccines, and one detecting antibodies elicited by both infection and vaccination. We used Bayesian statistical models to estimate the proportion of the population that was naturally infected and the proportion protected due to vaccination. Findings: We estimated that the risk of prior infection of Latinx residents was 5.3 (95% CI: 3.2 - 10.3) times greater than the risk of white residents aged 18-64 and that white San Francisco residents over the age of 65 were twice as likely (2.0, 95% CI: 1.1 - 4.6) to be vaccinated as Black residents. We also found socioeconomically deprived zipcodes in the city had high probabilities of natural infections and lower vaccination coverage than wealthier zipcodes. Interpretation: Using a platform we created for SARS-CoV-2 serologic data collection in San Francisco, we characterized and quantified the stark disparities in infection rates and vaccine coverage by demographic groups over the first year of the pandemic. While the arrival of the SARS-CoV-2 vaccine has created a 'light at the end of the tunnel' for this pandemic, ongoing challenges in achieving and maintaining equity must also be considered. Funding: NIH, NIGMS, Schmidt Science Fellows in partnership with the Rhodes Trust and the Chan Zuckerberg Biohub. Competing Interests: Declaration of Interests The authors have no conflicts of interest to declare. |
| التعليقات: | Update in: Nat Commun. 2022 May 4;13(1):2451. (PMID: 35508478) |
| References: | JAMA Health Forum. 2021 Apr 1;2(4):e210612. (PMID: 36218806) MMWR Morb Mortal Wkly Rep. 2021 Mar 26;70(12):431-436. (PMID: 33764963) Clin Infect Dis. 2021 Jul 30;73(Suppl 2):S127-S135. (PMID: 32821935) Soc Sci Med. 2021 Mar;272:113638. (PMID: 33414032) JAMA Health Forum. 2021 Mar 1;2(3):e210264. (PMID: 36218461) Clin Infect Dis. 2021 Jul 15;73(2):324-327. (PMID: 32744615) Nat Commun. 2021 Jun 11;12(1):3566. (PMID: 34117227) PLoS One. 2021 Sep 20;16(9):e0257111. (PMID: 34543291) Transl Behav Med. 2020 Aug 7;10(3):516-519. (PMID: 32542349) Sci Adv. 2021 Jul 30;7(31):. (PMID: 34330709) |
| معلومات مُعتمدة: | K24 AI144048 United States AI NIAID NIH HHS; R35 GM138361 United States GM NIGMS NIH HHS; U24 GM132013 United States GM NIGMS NIH HHS |
| تواريخ الأحداث: | Date Created: 20211013 Latest Revision: 20240403 |
| رمز التحديث: | 20240403 |
| مُعرف محوري في PubMed: | PMC8509086 |
| DOI: | 10.1101/2021.10.06.21264573 |
| PMID: | 34642695 |
| قاعدة البيانات: | MEDLINE |
| DOI: | 10.1101/2021.10.06.21264573 |
|---|